Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms
Retrieved on:
Monday, October 4, 2021
Sleep, Clinical trial, Man, IPSS, American Urological Association, Collection, Urination, BPH, Sale, Patient, Frustration, Professor, International Prostate Symptom Score, Urology, Urethra, Principal, Soldier Meadows hot spring system, Prostate, SAN, Retention rate, University of Texas Southwestern Medical Center, Safety, Quality of life, Spring system, GLOBE, Department, Medical imaging, Pharmaceutical industry
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc. , a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic hyperplasia (BPH), has initiated the BREEZE pivotal clinical trial to evaluate its Spring System.
- The symptoms associated with enlarged prostate have a substantial impact on patients quality of life, said Dr. Roehrborn.
- I am encouraged by the potential for the Spring treatment to improve the patient experience and am proud to be part of this rigorous clinical trial program.
- The BREEZE trial is a prospective, multicenter, controlled study in patients with lower urinary tract symptoms due to enlarged prostate.